Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 3 , Pages 210-216 , March 2010

Implications of Extending the ADHD Age-of-Onset Criterion to Age 12: Results from a Prospectively Studied Birth Cohort

  • Guilherme Polanczyk, M.D., Ph.D.

      Affiliations

    • Duke University
    • University of São Paulo Medical School & National Institute for Developmental Psychiatry, Brazil
    • Corresponding Author InformationCorrespondence to: Dr. Polanczyk, Department of Psychiatry, University of São Paulo Medical School, Rua Dr. Ovidio Pires de Campos 785, 05453-010 São Paulo, SP–Brazil
    • ,
  • Avshalom Caspi, Ph.D.

      Affiliations

    • Duke University
    • Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, England
    • ,
  • Renate Houts, Ph.D.

      Affiliations

    • Duke University
    • ,
  • Scott H. Kollins, Ph.D.

      Affiliations

    • Duke University
    • ,
  • Luis Augusto Rohde, M.D., Ph.D.

      Affiliations

    • Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil
    • ,
  • Terrie E. Moffitt, Ph.D.

      Affiliations

    • Duke University
    • Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, England

,Accepted 21 December 2009.

References 

  1. Regier DA, Narrow WE, Kuhl EA, Kupfer DJ. The conceptual development of DSM-V. Am J Psychiatry. 2009;166:645–650
  2. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:1204–1210
  3. Rohde LA. Is there a need to reformulate attention deficit hyperactivity disorder criteria in future nosologic classifications?. Child Adolesc Psychiatr Clin North Am. 2008;17:405–420
  4. Todd RD, Huang H, Henderson CA. Poor utility of the age of onset criterion for DSM-IV attention deficit/hyperactivity disorder: recommendations for DSM-V and ICD-11. J Child Psychol Psychiatry. 2008;49:942–949
  5. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948–1956
  6. McGough JJ, McCracken JT. Adult attention deficit hyperactivity disorder: moving beyond DSM-IV. Am J Psychiatry. 2006;163:1673–1675
  7. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948
  8. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet. 1998;351:429–433
  9. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997;36:1211–1221
  10. Barkley RA, Murphy KR, Fischer M. DSM symptom utility and the issue of age of onset (What the Science Says). In:  Barkley RA,  Murphy KR,  Fischer M editor. ADHD in Adults. New York: Guilford Press; 2008;p. 78–129
  11. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid?. Am J Psychiatry. 2006;163:1720–1729
  12. Sayal K, Goodman R. Do parental reports of child hyperkinetic disorder symptoms at school predict teacher ratings?. Eur Child Adolesc Psychiatry. 2009;18:336–344
  13. Kieling C, Kieling RR, Rohde LA, et al. The age at onset of Attention Deficit Hyperactivity Disorder. Am J Psychiatry. 2010;167:14–16
  14. Trouton A, Spinath FM, Plomin R. Twins early development study (TEDS): a multivariate, longitudinal genetic investigation of language, cognition and behavior problems in childhood. Twin Res. 2002;5:444–448
  15. Moffitt TE. Teen-aged mothers in contemporary Britain. J Child Psychol Psychiatry. 2002;43:727–742
  16. Jaffee SR, Moffitt TE, Caspi A, Taylor A, Arseneault L. Influence of adult domestic violence on children's internalizing and externalizing problems: an environmentally informative twin study. J Am Acad Child Adolesc Psychiatry. 2002;41:1095–1103
  17. Caspi A, Langley K, Milne B, et al. A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2008;65:203–210
  18. Kuntsi J, Eley TC, Taylor A, et al. The co-occurrence of ADHD and low IQ has genetic origins. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:41–47
  19. Trzesniewski KH, Moffitt TE, Caspi A, Taylor A, Maughan B. Revisiting the association between reading achievement and antisocial behavior: new evidence of an environmental explanation from a twin study. Child Dev. 2006;77:72–88
  20. Wechsler D. Weshler Preschool and Primary Scale of Intelligence–Revised. London: Psychological Corporation, Harcourt Brace; 1990;
  21. Sattler J. Assessment of Children: WISC-III and WPPSI-R Supplement. San Diego: Jerome M. Sattler; 1992;
  22. Grodzinsky GM, Diamond R. Frontal lobe functioning in boys with attention-deficit hyperactivity disorder. Dev Neuropsychol. 1992;8:427–445
  23. Gerstadt CL, Hong YJ, Diamond A. The relationship between cognition and action: performance of children 3 1/2-7 years old on a Stroop-like day-night test. Cognition. 1994;53:129–153
  24. Baddeley AD. Exploring the central executive. Q J Exp Psychol. 1996;49A:5–28
  25. Baddeley AD. Working Memory. Oxford: Clarendon Press; 1986;
  26. Kovacs M. Children's Depression Inventory (CDI) Manual. Toronto, ON: Multi-Health Systems; 1992;
  27. March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36:554–565
  28. Buckler JM, Green M. Birth weight and head circumference standards for English twins. Arch Dis Child. 1994;71:516–521
  29. Maughan B, Taylor A, Caspi A, Moffitt TE. Prenatal smoking and early childhood conduct problems: testing genetic and environmental explanations of the association. Arch Gen Psychiatry. 2004;61:836–843
  30. Williams RL. A note on robust variance estimaton for cluster-correlated data. Biometrics. 2000;56:645–646
  31. STATA. Version 9.0. Manuals. College Station, TX: Stata Corporation; 2005;
  32. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602
  33. Rohde LA, Biederman J, Zimmermann H, Schmitz M, Martins S, Tramontina S. Exploring ADHD age-of-onset criterion in Brazilian adolescents. Eur Child Adolesc Psychiatry. 2000;9:212–218
  34. Gjone H, Novik TS. Parental ratings of behavior problems—a twin and general-population comparison. J Child Psychol Psychiatry. 1995;36:1213–1224
  35. Levy F, Hay D, McLaughlin M, Wood C, Waldman I. Twin-sibling differences in parental reports of ADHD, speech, reading, and behavioural problems. J Child Psychol Psychiatry. 1996;37:569
  36. van den Oord EJ, Koot HM, Boomsma DI, Verhulst FC, Orlebeke JF. A twin-singleton comparison of problem behavior in 2 to 3 year-olds. J Child Psychol Psychiatry. 1995;36:449–458
  37. Kendler KS, Martin NG, Heath AC, Eaves LJ. Self-report psychiatric symptoms in twins and their nontwin relatives: are twins different?. Am J Med Genet B Neuropsychiatr Genet. 1995;60:588–591
  38. Johnson W, Krueger RF, Bouchard TJ, McGue M. The personalities of twins: just ordinary folks. Twin Res. 2002;5:125–131
  39. Moilanen I, Linna SL, Ebeling H, et al. Are twins' behavioural/emotional problems different from singletons'?. Eur Child Adolesc Psychiatry. 1999;8:62–67

 This article is discussed by Dr. Russell A. Barkley in an editorial on page 205.

 This research was supported by the UK Medical Research Council (G9806489, G0100527, and G0601483).

 Disclosure: Dr. Polanczyk has served as a speaker for Novartis and is a recipient of a 2008 National Alliance of Research on Schizophrenia and Depression (NARSAD) Young Investigator Award. Dr. Kollins has received research support and/or consultant fees from Addrenex Pharmaceuticals, Otsuka Pharmaceuticals, Shire Pharmaceuticals, the National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and Environmental Protection Agency (EPA). Dr. Rohde has served as a speaker and/or consultant for Eli Lilly, Janssen-Cilag, and Novartis in the last 3 years. Currently, his only industry-related activity is taking part in the advisory board/speakers' bureau for Eli Lilly and Novartis. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him have received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Abbott, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Novartis, and Shire. Dr. Houts, Caspi, and Moffitt report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(09)00071-9

doi: 10.1016/j.jaac.2009.12.014

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 3 , Pages 210-216 , March 2010

Article Tools